[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100408358":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":28,"centralContacts":32,"locations":41,"responsibleParty":69,"collaborators":72,"id":83,"slug":84,"hasResults":85,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":89,"eligibilityCriteria":90,"healthyVolunteers":85,"sex":91,"minAge":92,"maxAge":25,"enrollmentInfo":93,"targetDuration":25,"studyType":96,"phases":97,"briefSummary":99,"conditions":100,"keywords":25,"overallStatus":58,"whyStopped":25,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":111},{"fullName":5,"class":6},"George Washington University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Zanamivir","EXPERIMENTAL","In the treatment group, participants weighing less than 50 kg will receive 12 mg\u002Fkg and those weighing 50 kg and above will receive 600 mg as the initial dose intravenously every twelve hours for 5 days adjusted for renal function.",[13],"Drug: Zanamivir",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR","In the placebo group, participants will receive placebo normal saline solution intravenously every twelve hours for 5 days.",[19],"Other: Placebo",[21,26],{"type":22,"name":9,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Intravenous zanamivir",[9],null,{"type":6,"name":15,"description":17,"armGroupLabels":27,"otherNames":25},[15],[29],{"name":30,"affiliation":5,"role":31},"Aileen Chang, MD","PRINCIPAL_INVESTIGATOR",[33,38],{"name":34,"role":35,"phone":36,"phoneExt":25,"email":37},"Aileen Y Chang, MD","CONTACT","202-741-6562","chang@email.gwu.edu",{"name":39,"role":35,"phone":36,"phoneExt":25,"email":40},"Alfonso Sucerquia, MD","alfonso.sucerquiahernandez@email.gwu.edu",[42,56],{"facility":43,"status":44,"city":45,"state":46,"zip":47,"country":48,"countryCode":49,"cosmosGeoPoint":50,"geoPoint":55,"contacts":25},"Cien Salud IPS SAS","ACTIVE_NOT_RECRUITING","Barranquilla","Atlántico","080020","Colombia","CO",{"type":51,"coordinates":52},"Point",[53,54],-74.78132,10.96854,{"lat":54,"lon":53},{"facility":57,"status":58,"city":45,"state":48,"zip":47,"country":48,"countryCode":49,"cosmosGeoPoint":59,"geoPoint":61,"contacts":62},"Clinica de la Costa SAS","RECRUITING",{"type":51,"coordinates":60},[53,54],{"lat":54,"lon":53},[63,66],{"name":64,"role":35,"phone":25,"phoneExt":25,"email":65},"Andres Cadena, MD","acadena@clinicadelacosta.co",{"name":67,"role":35,"phone":25,"phoneExt":25,"email":68},"Camilo Fernandez","cfernandez@clinicadelacosta.co",{"type":31,"investigatorFullName":70,"investigatorTitle":71,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"Aileen Y Chang","PI",[73,76,79,81],{"name":74,"class":75},"Naval Medical Research Center","FED",{"name":77,"class":78},"Clinica de la Costa","UNKNOWN",{"name":80,"class":78},"Global Disease Research",{"name":82,"class":78},"Universidad Libre de Barranquilla","100408358","phase-2-zanamivir-treatment-of-vascular-permeability-in-dengue-zap-dengue-100408358",false,"NCT04597437","Zanamivir Treatment of Vascular Permeability in Dengue (ZAP-DENGUE)","Zanamivir Treatment of Vascular Permeability in Dengue (ZAP-DENGUE): A Pilot Randomized Controlled Trial","ZAP-DENGUE","Inclusion Criteria:\n\n1. Provision of signed and dated informed consent form.\n2. Stated willingness to comply with all study procedures and availability for the duration of the study.\n3. Male or female, aged \\>7 years\n4. Willingness to receive intravenous medication and be willing to adhere to the medication regimen\n5. Have a diagnosis of dengue by dengue NS1 rapid test\n6. Have had a self-informed fever \\>38 degrees C in the last 3 days.\n7. Have dengue with warning signs as per the 2009 WHO criteria including one of the following: abdominal pain or tenderness, persistent vomiting, clinical fluid accumulation, mucosal bleeding, lethargy, restlessness, liver enlargement over 2 cm, augmented hematocrit, thrombocytopenia or severe dengue defined as dengue with severe plasma leakage leading to dengue shock and\u002For fluid accumulation with respiratory distress; severe hemorrhage; severe organ impairment (hepatic damage, renal impairment, cardiomyopathy, encephalopathy or encephalitis).\n8. Enrollment in EPS (Entidadas Promotoras de Salud) or Sistema General de Seguridad Social en Salud (SGSSS)- Colombian Public Health Insurance.\n\nExclusion Criteria:\n\n1. Pregnancy or lactation\n2. Children in Care of the state\n3. Patients who are unlikely to survive 48 hours\n4. Unstable cardiac disease or arrhythmia at baseline\n5. History of significant cardiac disease\n6. Treatment with another investigational drug or other intervention within 1 month.\n7. Encephalitis or unable to consent","ALL","7 Years",{"count":94,"type":95},74,"ESTIMATED","INTERVENTIONAL",[98],"PHASE2","ZAP-DENGUE is a pilot randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of five days of intravenous zanamivir treatment to treat vascular permeability syndrome which is the main cause of death in dengue fever.",[101],"Dengue Fever","2025-07-23",{"date":104,"type":105},"2025-07-28","ACTUAL",{"date":107,"type":105},"2024-03-15",{"date":109,"type":95},"2026-09-30",{"name":5,"class":6},2]